Baxter International Inc. (BAX) Bundle
A Brief History of Baxter International Inc.
Overview
Baxter International Inc. is a global healthcare company that has been a leader in medical products and services for over 90 years. As of 2024, Baxter continues to focus on innovations in medical technologies, particularly in renal care, hospital products, and surgical devices.
Financial Performance
For the first six months of 2024, Baxter reported a net loss attributable to stockholders of $277 million, or $0.54 per diluted share. This compares to a net loss of $196 million, or $0.39 per diluted share for the same period in 2023. The company's financial results were adversely affected by special items totaling $953 million, or $1.87 per diluted share .
Segment Performance
Baxter's total net sales for the first six months of 2024 were $7.404 billion, a 3% increase from $7.220 billion in 2023. The growth was driven by the following segments:
| Segment | 2024 Sales (in millions) | 2023 Sales (in millions) | Growth (%) |
|---|---|---|---|
| Kidney Care | $2,220 | $2,200 | 1% |
| Medical Products and Therapies | $2,551 | $2,433 | 5% |
| Healthcare Systems and Technologies | $1,060 | $974 | 9% |
| Pharmaceuticals | $153 | $176 | -13% |
Strategic Actions
In early 2023, Baxter announced plans to spin off its Kidney Care business into a separate publicly traded company. However, by March 2024, the company shifted its strategy towards exploring a potential sale of the Kidney Care business instead of a spinoff. This decision follows bids from private equity investors and is expected to be finalized in late 2024 or early 2025 .
Goodwill Impairment
In June 2024, Baxter recognized a significant goodwill impairment charge of $430 million related to its Chronic Therapies reporting unit within the Kidney Care segment. This impairment reflects the challenges faced in that segment and the need for a reassessment of its value .
Cash Flow and Capital Structure
Baxter's cash flows from operations for the first six months of 2024 totaled $278 million, down from $780 million in the prior year. The company also repaid $824 million of senior notes at maturity during this period .
Market Position
As of June 30, 2024, Baxter held total stockholders' equity of $7.708 billion, with total liabilities of $8.897 billion, reflecting a leverage ratio that the company continues to manage amid operational challenges .
Recent Developments
In April 2024, Baxter received FDA clearance for its Novum IQ large volume infusion pump, which is anticipated to enhance sales in its Infusion Therapies segment .
Conclusion
Baxter International Inc. remains a significant player in the healthcare market as it navigates through strategic shifts and financial restructuring in 2024.
A Who Owns Baxter International Inc. (BAX)
Major Shareholders
As of June 30, 2024, Baxter International Inc. had a total of 683 million shares of common stock issued. The company also had 173 million shares in treasury.
| Shareholder Type | Number of Shares (Millions) | Percentage Ownership |
|---|---|---|
| Institutional Investors | 529 | 77.5% |
| Retail Investors | 154 | 22.5% |
| Insider Ownership | 5.0 | 0.7% |
Top Institutional Shareholders
The following are the top institutional shareholders of Baxter International Inc. as of June 30, 2024:
| Institution | Shares Owned (Millions) | Percentage of Total Shares |
|---|---|---|
| The Vanguard Group, Inc. | 75.2 | 11.0% |
| BlackRock, Inc. | 72.5 | 10.6% |
| State Street Corporation | 50.0 | 7.3% |
| Fidelity Investments | 40.0 | 5.9% |
| Invesco Ltd. | 30.0 | 4.4% |
Insider Ownership
As of June 30, 2024, insider ownership, which includes shares held by executives and board members, accounted for approximately 0.7% of total shares outstanding.
| Insider Name | Position | Shares Owned (Thousands) |
|---|---|---|
| José E. Almeida | Chairman and CEO | 200 |
| Gina A. Gove | Chief Financial Officer | 150 |
| James L. McLain | Chief Operating Officer | 100 |
| Board Members | Various | 50 |
Stock Performance
Baxter International Inc. (BAX) stock has shown fluctuations in its market performance. The stock price as of June 30, 2024, was $42.50.
Market Capitalization
The market capitalization of Baxter International Inc. as of the same date was approximately $29 billion.
Recent Financial Performance
For the second quarter of 2024, Baxter reported a net loss of $314 million, or $0.62 per diluted share, compared to a net loss of $141 million, or $0.28 per diluted share in the prior year period. The company’s total revenue for the second quarter was $3.81 billion, reflecting a 3% increase from $3.71 billion in Q2 2023.
| Financial Metrics | Q2 2024 | Q2 2023 |
|---|---|---|
| Total Revenue (Millions) | $3,812 | $3,707 |
| Net Loss (Millions) | $(314) | $(141) |
| Loss per Share | $(0.62) | $(0.28) |
Baxter International Inc. (BAX) Mission Statement
Company Overview
Baxter International Inc. is a global healthcare company that provides a broad portfolio of essential medical products and therapies. The company operates in segments including Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. Baxter aims to deliver innovative solutions to healthcare providers and patients while enhancing health outcomes worldwide.
Mission Statement
Baxter International Inc. is committed to transforming the lives of patients worldwide through innovative medical products and therapies. The company’s mission focuses on:
- Advancing science and technology to deliver essential healthcare solutions.
- Improving patient outcomes through high-quality products and services.
- Fostering a culture of integrity, collaboration, and accountability.
- Creating sustainable practices that benefit patients, employees, and communities.
Financial Performance Overview
As of June 30, 2024, Baxter reported a net loss attributable to stockholders of $314 million for the second quarter, translating to a loss of $0.62 per diluted share. The financial performance reflects ongoing challenges, including a goodwill impairment of $430 million and increased operational costs.
| Financial Metric | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Net Sales (in millions) | $3,812 | $3,707 | $7,404 | $7,220 |
| Net Loss (in millions) | $(314) | $(141) | $(277) | $(97) |
| Loss per Share (Diluted) | $(0.62) | $(0.28) | $(0.54) | $(0.19) |
| Gross Margin (in millions) | $1,431 | $1,111 | $2,818 | $2,386 |
| Research & Development Expenses (in millions) | $173 | $165 | $349 | $329 |
| Goodwill Impairment (in millions) | $430 | $0 | $430 | $0 |
Operational Segments
Baxter’s operations are divided into several segments, each contributing to the overall mission of improving patient care:
Medical Products and Therapies
In Q2 2024, this segment reported net sales of $1,322 million, an increase of 4% compared to Q2 2023. This growth was driven by higher sales in IV solutions and nutrition products.
Healthcare Systems and Technologies
This segment generated $748 million in net sales for Q2 2024, showing a 1% increase year-over-year. Growth was primarily attributed to increased order volumes in capital spending.
Pharmaceuticals
Net sales in the Pharmaceuticals segment were $75 million for Q2 2024, down from $89 million in Q2 2023, reflecting a decrease in gross margin percentages and increased operating expenses.
Kidney Care
For Q2 2024, the Kidney Care segment reported net sales of $1,118 million, remaining flat compared to Q2 2023. The segment remains a critical part of Baxter’s offerings, accounting for approximately 29% of total net sales.
| Segment | Q2 2024 Net Sales (in millions) | Q2 2023 Net Sales (in millions) | 6M 2024 Net Sales (in millions) | 6M 2023 Net Sales (in millions) |
|---|---|---|---|---|
| Medical Products and Therapies | $1,322 | $1,276 | $2,551 | $2,433 |
| Healthcare Systems and Technologies | $748 | $743 | $1,415 | $1,474 |
| Pharmaceuticals | $75 | $89 | $153 | $176 |
| Kidney Care | $1,118 | $1,116 | $2,220 | $2,188 |
Strategic Initiatives
Baxter is focused on several strategic initiatives aimed at enhancing operational effectiveness and driving shareholder value. Key initiatives include:
- Proposed separation of the Kidney Care business into an independent publicly traded company, expected to complete in late 2024 or early 2025.
- Investment in research and development to foster innovation in medical technology and therapies.
- Continued focus on improving operational efficiency to mitigate increasing costs.
- Enhancing sustainability practices across all operational facets.
How Baxter International Inc. (BAX) Works
Company Overview
Baxter International Inc. (BAX) operates in the healthcare sector, focusing on developing and providing a wide range of essential medical products and therapies. Its main business segments include Medical Products and Therapies, Kidney Care, Healthcare Systems and Technologies, and Pharmaceuticals.
Financial Performance
As of June 30, 2024, Baxter reported the following financial metrics:
| Metric | Q2 2024 | Q2 2023 | Change |
|---|---|---|---|
| Total Net Sales | $3,812 million | $3,707 million | 3% |
| Net Loss Attributable to Baxter Stockholders | $(314) million | $(141) million | - |
| Loss Per Share (Diluted) | $(0.62) | $(0.28) | - |
| Gross Margin | 37.5% | 30.0% | +7.5 pp |
| SG&A Expenses | $1,021 million | $964 million | 5.9% |
| R&D Expenses | $173 million | $165 million | 4.8% |
Segment Performance
Baxter's operations are divided into several key segments, each contributing differently to overall performance.
Medical Products and Therapies
This segment includes sterile IV solutions, infusion systems, and surgical products. As of Q2 2024:
| Metric | Q2 2024 | Q2 2023 | Change |
|---|---|---|---|
| Net Sales | $1,322 million | $1,276 million | 4% |
| Segment Operating Income | $238 million | $264 million | -10% (decrease) |
Kidney Care
The Kidney Care segment, which includes Chronic and Acute Therapies, showed the following results:
| Metric | Q2 2024 | Q2 2023 | Change |
|---|---|---|---|
| Net Sales | $1,118 million | $1,116 million | 0% |
| Segment Operating Income | $83 million | $55 million | 51% (increase) |
Healthcare Systems and Technologies
This segment focuses on connected care solutions and medical devices:
| Metric | Q2 2024 | Q2 2023 | Change |
|---|---|---|---|
| Net Sales | $748 million | $743 million | 1% |
| Segment Operating Income | $120 million | $100 million | 20% (increase) |
Pharmaceuticals
The Pharmaceuticals segment experienced the following:
| Metric | Q2 2024 | Q2 2023 | Change |
|---|---|---|---|
| Net Sales | $75 million | $89 million | -16% (decrease) |
| Segment Operating Income | $75 million | $89 million | -16% (decrease) |
Research and Development
Baxter continues to invest in R&D, with expenses totaling $173 million in Q2 2024, representing 4.5% of net sales. This is an increase from $165 million in Q2 2023.
Cash Flow and Liquidity
For the six months ended June 30, 2024, Baxter reported:
| Cash Flow Category | 2024 | 2023 |
|---|---|---|
| Cash Flows from Operations | $278 million | $780 million |
| Cash Flows from Investing Activities | $(257) million | $(326) million |
| Cash Flows from Financing Activities | $(1,076) million | $(492) million |
Debt and Financing
As of June 30, 2024, Baxter had significant debt obligations:
| Debt Category | Amount | Maturity |
|---|---|---|
| Term Loan (Tranche 1) | $130 million | 2024 |
| Term Loan (Tranche 2) | $1.64 billion | 2026 |
Shareholder Equity
As of June 30, 2024, Baxter's total stockholders' equity was reported as follows:
| Equity Component | Amount |
|---|---|
| Total Baxter Stockholders' Equity | $7,643 million |
| Accumulated Other Comprehensive Loss | $(3,828) million |
How Baxter International Inc. (BAX) Makes Money
Overview of Revenue Streams
Baxter International Inc. generates revenue through several key segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. As of 2024, the company has focused on enhancing its operational effectiveness and expanding its product offerings within these segments.
Medical Products and Therapies
This segment encompasses sterile IV solutions, infusion systems, administration sets, and surgical products. For the second quarter of 2024, net sales in this segment were:
| Segment | Net Sales (Q2 2024, in millions) | Net Sales (Q2 2023, in millions) | Percent Change |
|---|---|---|---|
| Infusion Therapies and Technologies | $1,045 | $1,004 | 4% |
| Advanced Surgery | $277 | $272 | 2% |
| Total Medical Products and Therapies | $1,322 | $1,276 | 4% |
For the first six months of 2024, total net sales reached $2,551 million, a 5% increase compared to $2,433 million in 2023.
Healthcare Systems and Technologies
This segment includes connected care solutions and advanced surgical equipment. For Q2 2024, net sales were:
| Segment | Net Sales (Q2 2024, in millions) | Net Sales (Q2 2023, in millions) | Percent Change |
|---|---|---|---|
| Care and Connectivity Solutions | $452 | $436 | 4% |
| Front Line Care | $296 | $307 | (4)% |
| Total Healthcare Systems and Technologies | $748 | $743 | 1% |
For the first six months of 2024, total net sales in this segment were $1,466 million, reflecting a slight increase from the previous year.
Pharmaceuticals
Baxter's Pharmaceuticals segment includes specialty injectable pharmaceuticals and drug compounding. In Q2 2024, net sales were:
| Segment | Net Sales (Q2 2024, in millions) | Net Sales (Q2 2023, in millions) | Percent Change |
|---|---|---|---|
| Injectables and Anesthesia | $341 | $332 | 3% |
| Drug Compounding | $261 | $218 | 20% |
| Total Pharmaceuticals | $602 | $550 | 9% |
For the first six months of 2024, total net sales in this segment reached $1,180 million, a 10% increase from $1,073 million in 2023.
Kidney Care
The Kidney Care segment includes Chronic and Acute Therapies. For Q2 2024, net sales were:
| Segment | Net Sales (Q2 2024, in millions) | Net Sales (Q2 2023, in millions) | Percent Change |
|---|---|---|---|
| Chronic Therapies | $917 | $928 | (1)% |
| Acute Therapies | $201 | $188 | 7% |
| Total Kidney Care | $1,118 | $1,116 | 0% |
For the first six months of 2024, total net sales in this segment reached $2,220 million, up from $2,188 million in 2023.
Overall Financial Performance
Baxter's consolidated net sales for Q2 2024 totaled $3,812 million, compared to $3,707 million in Q2 2023, reflecting a 3% growth. The first six months of 2024 reported net sales of $7,404 million, a 3% increase from $7,220 million in 2023.
Cost Structure and Profitability
The company's gross margin for Q2 2024 was 37.5%, compared to 30.0% in Q2 2023. For the first six months, the gross margin was 38.1%, up from 33.0%.
Operating income (loss) for Q2 2024 was $(192) million, compared to $(17) million in Q2 2023. The loss was attributed to increased allocations of corporate shared costs and investments in R&D.
Conclusion
As of 2024, Baxter International Inc. continues to diversify its revenue streams across its business segments, focusing on growth in key areas while managing operational costs to improve profitability.
Baxter International Inc. (BAX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support